HC
CRSP icon

Henshaw Capital’s CRISPR Therapeutics CRSP Stock Holding History

Henshaw Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,022
Closed -$226K – 330
2021
Q3 		$226K Buy
2,022
+780
+63% +$98K 0.01% 303
2021
Q2 		$201K Buy
+1,242
New +$151K 0.01% 341

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Henshaw Capital's CRSP Position: Q4 2021 in Review

Henshaw Capital sold out of CRISPR Therapeutics (CRSP) in Q4 2021, closing a stake of 2,022 shares — an estimated $226K sold.

Henshaw Capital first reported a position in CRSP in Q2 2021 and held it in 2 quarters. The position peaked at $226K in Q3 2021. 446 funds tracked by Wall St. Rank hold CRSP as of Q4 2021.

  • Henshaw Capital reported no remaining CRISPR Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Henshaw Capital sold 2,022 CRISPR Therapeutics shares in Q4 2021, an estimated $226K.
  • Henshaw Capital first reported a position in CRISPR Therapeutics in Q2 2021 and held it in 2 quarters.
  • Henshaw Capital's CRISPR Therapeutics position peaked at $226K in Q3 2021.
  • 446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2021.

Based on Henshaw Capital's 13F filing for Q4 2021, filed 28 May 2026.